Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 4, 2012, Pages 575-583

  Blaser, Bradley W ^a   Kim, Haesook T ^b   Alyea, Edwin P ^a   Ho, Vincent T ^a   Cutler, Corey ^a   Armand, Philippe ^a   Koreth, John ^a   Antin, Joseph H ^a   Plutzky, Jorge ^a   Soiffer, Robert J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

GVHD; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia; Lipid; Statin

Indexed keywords

BUSULFAN; CORTICOSTEROID; FLUDARABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; RAPAMYCIN; TACROLIMUS; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OBESITY; PHYSICIAN; PRACTICE GUIDELINE; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RETROSPECTIVE STUDIES; RISK; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858078790     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.08.003     Document Type: Article

References (45)

1. Tichelli A., Bucher C., Rovó A., et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood 2007, 110:3463-3471.
2. Armenian S.H., Bhatia S. Cardiovascular disease after hematopoietic cell transplantation-lessons learned. Haematologica 2008, 93:1132-1136.
3. Baker K.S., Ness K.K., Steinberger J., et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood 2007, 109:1765-1772.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. National Cholesterol Education Program NCEP Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III.
5. Socié G., Mary J.Y., Esperou H., et al. Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2001, 113:194-201.
6. Majhail N.S., Flowers M.E., Ness K.K., et al. High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2009, 43:49-54.
7. Lee S.J., Seaborn T., Mao F.J., et al. Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:416-420.
8. Chow E.J., Mueller B.A., Baker K.S., et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med 2011, 155:21-32.
9. Mann D., Reynolds K., Smith D., Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program Guidelines. Ann Pharmacother 2008, 42:1208.
10. Hamadani M., Awan F.T., Devine S.M. The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. Blood 2008, 111:3901-3902.
11. Rotta M., Storer B.E., Storb R.F., et al. Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. Blood 2010, 115:1288-1295.
12. Rotta M., Storer B.E., Storb R., et al. Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1463-1466.
13. Harrell F. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis 2001, Springer-Verlag, New York.
14. Pasternak R.C., Smith S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002, 40:567-572.
15. Griffith M.L., Savani B.N., Boord J.B. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. Blood 2010, 116:1197-1204.
16. Taskinen M., Saarinen-Pihkala U.M., Hovi L., Lipsanen-Nyman M. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000, 356:993-997.
17. Annaloro C., Usardi P., Airaghi L., et al. Prevalence of metabolic syndrome in long-term survivors of hematopoietic stem cell transplantation. Bone Marrow Transplant 2008, 41:797-804.
18. Armenian S.H., Sun C.-L., Mills G., et al. Predictors of late cardiovascular complications in survivors of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:1138-1144.
19. Ridker P.M., Danielson E., Fonseca F.A.H., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
20. Kobashigawa J.A., Katznelson S., Laks H., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
21. Kobashigawa J.A., Moriguchi J.D., Laks H., et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005, 24:1736-1740.
22. Wenke K., Meiser B., Thiery J., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997, 96:1398-1402.
23. Wenke K., Meiser B., Thiery J., et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003, 107:93-97.
24. Mehra M.R., Raval N.Y. Metaanalysis of statins and survival in de novo cardiac transplantation. Transplant Proc 2004, 36:1539-1541.
25. Johnson B.A., Iacono A.T., Zeevi A., McCurry K.R., Duncan S.R. Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med 2003, 167:1271-1278.
26. Katznelson S., Wilkinson A.H., Kobashigawa J.A., et al. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation 1996, 61:1469-1474.
27. Navaneethan S.D., Perkovic V., Johnson D.W., Nigwekar S.U., Craig J.C., Strippoli G.F.M. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009, 2:CD005019.
28. Tuncer M., Süleymanlar G., Ersoy F.F., Yakupoĝlu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc 2000, 32:622-625.
29. Shirinsky I.V., Zheltova O.I., Solovyova N.Y., Kozlov V.A., Shirinsky V.S. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 2009, 38:23-27.
30. Okamoto H., Koizumi K., Kamitsuji S., et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007, 34:964-968.
31. Togha M., Karvigh S.A., Nabavi M., et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler 2010, 16:848-854.
32. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608.
33. Lanzillo R., Orefice G., Quarantelli M., et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 2010, 16:450-454.
34. Dunn S.E., Youssef S., Goldstein M.J., et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006, 203:401-412.
35. Zeiser R., Youssef S., Baker J., Kambham N., Steinman L., Negrin R.S. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood 2007, 110:4588-4598.
36. Tong J., Laport G., Lowsky R. Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma. Bone Marrow Transplant 2005, 36:739-740.
37. Hong R., Sequeira W. Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy. J Clin Rheumatol 2000, 6:324-327.
38. Ritzel U., Leonhardt U., Näther M., Schäfer G., Armstrong V.W., Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002, 36:454-458.
39. Stojakovic T., Putz-Bankuti C., Fauler G., et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007, 46:776-784.
40. Chalasani N., Aljadhey H., Kesterson J., Murray M.D., Hall S.D. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004, 126:1287-1292.
41. Abu Rajab M., Kaplan M.M. Statins in primary biliary cirrhosis: are they safe?. Dig Dis Sci 2010, 55:2086-2088.
42. Khorashadi S., Hasson N.K., Cheung R.C. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006, 4:902-907.
43. Rizzo J.D., Wingard J.R., Tichelli A., et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2006, 12:138-151.
44. Tichelli A., Passweg J., Wójcik D., et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2008, 93:1203-1210.
45. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.